Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 15 |
| 1.1 List of Tables | 9 | 7 |
| 1.2 List of Figures | 16 | 1 |
| 2 Introduction | 17 | 1 |
| 2.1 Ovarian Cancer Diagnostic Tests Overview | 17 | 1 |
| 3 Products under Development | 18 | 5 |
| 3.1 Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development | 18 | 1 |
| 3.2 Ovarian Cancer Diagnostic Tests - Pipeline Products by Territory | 19 | 1 |
| 3.3 Ovarian Cancer Diagnostic Tests - Pipeline Products by Regulatory Path | 20 | 1 |
| 3.4 Ovarian Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date | 21 | 1 |
| 3.5 Ovarian Cancer Diagnostic Tests - Ongoing Clinical Trials | 22 | 1 |
| 4 Ovarian Cancer Diagnostic Tests - Pipeline Products under Development by Companies | 23 | 8 |
| 4.1 Ovarian Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development | 23 | 4 |
| 4.2 Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development | 27 | 4 |
| 5 Ovarian Cancer Diagnostic Tests Companies and Product Overview | 31 | 116 |
| 5.1 A&G Pharmaceutical, Inc. Company Overview | 31 | 1 |
| 5.1.1 A&G Pharmaceutical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 31 | 2 |
| 5.2 Abnova Corporation Company Overview | 33 | 1 |
| 5.2.1 Abnova Corporation Pipeline Products &Ongoing Clinical Trials Overview | 33 | 2 |
| 5.3 Almac Diagnostics Limited Company Overview | 35 | 1 |
| 5.3.1 Almac Diagnostics Limited Pipeline Products &Ongoing Clinical Trials Overview | 35 | 1 |
| 5.4 ANGLE plc Company Overview | 36 | 1 |
| 5.4.1 ANGLE plc Pipeline Products &Ongoing Clinical Trials Overview | 36 | 3 |
| 5.5 AroCell AB Company Overview | 39 | 1 |
| 5.5.1 AroCell AB Pipeline Products &Ongoing Clinical Trials Overview | 39 | 1 |
| 5.6 ArtemixRx Company Overview | 40 | 1 |
| 5.6.1 ArtemixRx Pipeline Products &Ongoing Clinical Trials Overview | 40 | 1 |
| 5.7 Augusta University Company Overview | 41 | 1 |
| 5.7.1 Augusta University Pipeline Products &Ongoing Clinical Trials Overview | 41 | 1 |
| 5.8 Aurelium BioPharma Inc. Company Overview | 42 | 1 |
| 5.8.1 Aurelium BioPharma Inc. Pipeline Products &Ongoing Clinical Trials Overview | 42 | 3 |
| 5.9 Avant Diagnostics, Inc. Company Overview | 45 | 1 |
| 5.9.1 Avant Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 45 | 1 |
| 5.10 Axela Inc. Company Overview | 46 | 1 |
| 5.10.1 Axela Inc. Pipeline Products &Ongoing Clinical Trials Overview | 46 | 1 |
| 5.11 Ayanda Biosystems S.A. Company Overview | 47 | 1 |
| 5.11.1 Ayanda Biosystems S.A. Pipeline Products &Ongoing Clinical Trials Overview | 47 | 1 |
| 5.12 Becton, Dickinson and Company Company Overview | 48 | 1 |
| 5.12.1 Becton, Dickinson and Company Pipeline Products &Ongoing Clinical Trials Overview | 48 | 2 |
| 5.13 Bioindustry Park Silvano Fumero S.p.A. Company Overview | 50 | 1 |
| 5.13.1 Bioindustry Park Silvano Fumero S.p.A. Pipeline Products &Ongoing Clinical Trials Overview | 50 | 1 |
| 5.14 Ceres Nanosciences, Inc. Company Overview | 51 | 1 |
| 5.14.1 Ceres Nanosciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 51 | 2 |
| 5.15 Chronix Biomedical, Inc. Company Overview | 53 | 1 |
| 5.15.1 Chronix Biomedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 53 | 1 |
| 5.16 Clarient, Inc. Company Overview | 54 | 1 |
| 5.16.1 Clarient, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 54 | 1 |
| 5.17 ClavGen Therapeutics LLC Company Overview | 55 | 1 |
| 5.17.1 ClavGen Therapeutics LLC Pipeline Products &Ongoing Clinical Trials Overview | 55 | 1 |
| 5.18 Cleveland Diagnostics Inc. Company Overview | 56 | 1 |
| 5.18.1 Cleveland Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview | 56 | 1 |
| 5.19 Clovis Oncology, Inc. Company Overview | 57 | 1 |
| 5.19.1 Clovis Oncology, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 57 | 1 |
| 5.20 Courtagen Life Sciences, Inc. Company Overview | 58 | 1 |
| 5.20.1 Courtagen Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 58 | 1 |
| 5.21 Dako A/S Company Overview | 59 | 1 |
| 5.21.1 Dako A/S Pipeline Products &Ongoing Clinical Trials Overview | 59 | 1 |
| 5.22 Dana-Farber Cancer Institute, Inc. Company Overview | 60 | 1 |
| 5.22.1 Dana-Farber Cancer Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 60 | 1 |
| 5.23 Diazyme Laboratories Company Overview | 61 | 1 |
| 5.23.1 Diazyme Laboratories Pipeline Products &Ongoing Clinical Trials Overview | 61 | 4 |
| 5.24 Eventus Diagnostics, Inc. Company Overview | 65 | 1 |
| 5.24.1 Eventus Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 65 | 1 |
| 5.25 Exiqon A/S Company Overview | 66 | 1 |
| 5.25.1 Exiqon A/S Pipeline Products &Ongoing Clinical Trials Overview | 66 | 1 |
| 5.26 Exosomics Siena SpA Company Overview | 67 | 1 |
| 5.26.1 Exosomics Siena SpA Pipeline Products &Ongoing Clinical Trials Overview | 67 | 1 |
| 5.27 Fahy Gurteen UK Limited Company Overview | 68 | 1 |
| 5.27.1 Fahy Gurteen UK Limited Pipeline Products &Ongoing Clinical Trials Overview | 68 | 1 |
| 5.28 Foundation Medicine, Inc. Company Overview | 69 | 1 |
| 5.28.1 Foundation Medicine, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 69 | 2 |
| 5.29 French National Institute of Health and Medical Research Company Overview | 71 | 1 |
| 5.29.1 French National Institute of Health and Medical Research Pipeline Products &Ongoing Clinical Trials Overview | 71 | 1 |
| 5.30 Ganymed Pharmaceuticals AG Company Overview | 72 | 1 |
| 5.30.1 Ganymed Pharmaceuticals AG Pipeline Products &Ongoing Clinical Trials Overview | 72 | 1 |
| 5.31 GeneNews Limited Company Overview | 73 | 1 |
| 5.31.1 GeneNews Limited Pipeline Products &Ongoing Clinical Trials Overview | 73 | 2 |
| 5.32 Georgia Institute of Technology Company Overview | 75 | 1 |
| 5.32.1 Georgia Institute of Technology Pipeline Products &Ongoing Clinical Trials Overview | 75 | 1 |
| 5.33 GlycoZym Company Overview | 76 | 1 |
| 5.33.1 GlycoZym Pipeline Products &Ongoing Clinical Trials Overview | 76 | 1 |
| 5.34 H. Lee Moffitt Cancer Center &Research Institute, Inc. Company Overview | 77 | 1 |
| 5.34.1 H. Lee Moffitt Cancer Center &Research Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 77 | 1 |
| 5.35 Ikonisys, Inc. Company Overview | 78 | 1 |
| 5.35.1 Ikonisys, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 78 | 1 |
| 5.36 Inanovate (UK) Ltd. Company Overview | 79 | 1 |
| 5.36.1 Inanovate (UK) Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 79 | 1 |
| 5.37 InterGenetics Incorporated Company Overview | 80 | 1 |
| 5.37.1 InterGenetics Incorporated Pipeline Products &Ongoing Clinical Trials Overview | 80 | 1 |
| 5.38 IV Diagnostics, Inc. Company Overview | 81 | 1 |
| 5.38.1 IV Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 81 | 1 |
| 5.39 John Hopkins University Company Overview | 82 | 1 |
| 5.39.1 John Hopkins University Pipeline Products &Ongoing Clinical Trials Overview | 82 | 3 |
| 5.40 KIYATEC Inc. Company Overview | 85 | 1 |
| 5.40.1 KIYATEC Inc. Pipeline Products &Ongoing Clinical Trials Overview | 85 | 1 |
| 5.41 Lab Discoveries Ltd. Company Overview | 86 | 1 |
| 5.41.1 Lab Discoveries Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 86 | 1 |
| 5.42 Laboratorios SALVAT S.A. Company Overview | 87 | 1 |
| 5.42.1 Laboratorios SALVAT S.A. Pipeline Products &Ongoing Clinical Trials Overview | 87 | 1 |
| 5.43 Laboratory Corporation of America Holdings Company Overview | 88 | 1 |
| 5.43.1 Laboratory Corporation of America Holdings Pipeline Products &Ongoing Clinical Trials Overview | 88 | 2 |
| 5.44 Louisville Bioscience, Inc. Company Overview | 90 | 1 |
| 5.44.1 Louisville Bioscience, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 90 | 1 |
| 5.45 MabCure Inc. Company Overview | 91 | 1 |
| 5.45.1 MabCure Inc. Pipeline Products &Ongoing Clinical Trials Overview | 91 | 2 |
| 5.46 MDNA Life Sciences, Inc. Company Overview | 93 | 1 |
| 5.46.1 MDNA Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 93 | 2 |
| 5.47 MDxHealth SA Company Overview | 95 | 1 |
| 5.47.1 MDxHealth SA Pipeline Products &Ongoing Clinical Trials Overview | 95 | 2 |
| 5.48 Metabolon, Inc. Company Overview | 97 | 1 |
| 5.48.1 Metabolon, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 97 | 1 |
| 5.49 Milagen, Inc. Company Overview | 98 | 1 |
| 5.49.1 Milagen, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 98 | 1 |
| 5.50 Myriad Genetics, Inc. Company Overview | 99 | 1 |
| 5.50.1 Myriad Genetics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 99 | 2 |
| 5.51 Nanosphere, Inc. Company Overview | 101 | 1 |
| 5.51.1 Nanosphere, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 101 | 2 |
| 5.52 National University of Singapore Company Overview | 103 | 1 |
| 5.52.1 National University of Singapore Pipeline Products &Ongoing Clinical Trials Overview | 103 | 1 |
| 5.53 Novel Bio-spectrum Technologies, Inc. Company Overview | 104 | 1 |
| 5.53.1 Novel Bio-spectrum Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 104 | 1 |
| 5.54 Olympia Diagnostics, Inc Company Overview | 105 | 1 |
| 5.54.1 Olympia Diagnostics, Inc Pipeline Products &Ongoing Clinical Trials Overview | 105 | 1 |
| 5.55 Oncgnostics GmbH Company Overview | 106 | 1 |
| 5.55.1 Oncgnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview | 106 | 1 |
| 5.56 Oncimmune (USA) LLC Company Overview | 107 | 1 |
| 5.56.1 Oncimmune (USA) LLC Pipeline Products &Ongoing Clinical Trials Overview | 107 | 1 |
| 5.57 Orion Genomics LLC Company Overview | 108 | 1 |
| 5.57.1 Orion Genomics LLC Pipeline Products &Ongoing Clinical Trials Overview | 108 | 1 |
| 5.58 Oryzon Genomics SA Company Overview | 109 | 1 |
| 5.58.1 Oryzon Genomics SA Pipeline Products &Ongoing Clinical Trials Overview | 109 | 1 |
| 5.59 OTraces Inc. Company Overview | 110 | 1 |
| 5.59.1 OTraces Inc. Pipeline Products &Ongoing Clinical Trials Overview | 110 | 2 |
| 5.60 PeriRx LLC Company Overview | 112 | 1 |
| 5.60.1 PeriRx LLC Pipeline Products &Ongoing Clinical Trials Overview | 112 | 1 |
| 5.61 Phenomenome Discoveries, Inc. Company Overview | 113 | 1 |
| 5.61.1 Phenomenome Discoveries, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 113 | 1 |
| 5.62 Precision Biologics, Inc. Company Overview | 114 | 1 |
| 5.62.1 Precision Biologics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 114 | 1 |
| 5.63 Pronota NV Company Overview | 115 | 1 |
| 5.63.1 Pronota NV Pipeline Products &Ongoing Clinical Trials Overview | 115 | 1 |
| 5.64 Protagen AG Company Overview | 116 | 1 |
| 5.64.1 Protagen AG Pipeline Products &Ongoing Clinical Trials Overview | 116 | 1 |
| 5.65 Proteomika Company Overview | 117 | 1 |
| 5.65.1 Proteomika Pipeline Products &Ongoing Clinical Trials Overview | 117 | 1 |
| 5.66 Provista Diagnostics Inc. Company Overview | 118 | 1 |
| 5.66.1 Provista Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview | 118 | 1 |
| 5.67 RiboMed Biotechnologies, Inc. Company Overview | 119 | 1 |
| 5.67.1 RiboMed Biotechnologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 119 | 1 |
| 5.68 Roche Diagnostics International Ltd. Company Overview | 120 | 1 |
| 5.68.1 Roche Diagnostics International Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 120 | 2 |
| 5.69 Rosetta Genomics Ltd Company Overview | 122 | 1 |
| 5.69.1 Rosetta Genomics Ltd Pipeline Products &Ongoing Clinical Trials Overview | 122 | 2 |
| 5.70 SomaLogic, Inc. Company Overview | 124 | 1 |
| 5.70.1 SomaLogic, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 124 | 2 |
| 5.71 Soricimed Biopharma Inc. Company Overview | 126 | 1 |
| 5.71.1 Soricimed Biopharma Inc. Pipeline Products &Ongoing Clinical Trials Overview | 126 | 2 |
| 5.72 Stage I Diagnostics, Inc. Company Overview | 128 | 1 |
| 5.72.1 Stage I Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 128 | 1 |
| 5.73 SurExam Life Science &Technology Co. Company Overview | 129 | 1 |
| 5.73.1 SurExam Life Science &Technology Co. Pipeline Products &Ongoing Clinical Trials Overview | 129 | 1 |
| 5.74 Target Discovery, Inc. Company Overview | 130 | 1 |
| 5.74.1 Target Discovery, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 130 | 1 |
| 5.75 Teva Pharmaceutical Industries Ltd. Company Overview | 131 | 1 |
| 5.75.1 Teva Pharmaceutical Industries Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 131 | 2 |
| 5.76 The University of Adelaide Company Overview | 133 | 1 |
| 5.76.1 The University of Adelaide Pipeline Products &Ongoing Clinical Trials Overview | 133 | 1 |
| 5.77 The University of Texas MD Anderson Cancer Center Company Overview | 134 | 1 |
| 5.77.1 The University of Texas MD Anderson Cancer Center Pipeline Products &Ongoing Clinical Trials Overview | 134 | 1 |
| 5.78 Todos Medical Company Overview | 135 | 1 |
| 5.78.1 Todos Medical Pipeline Products &Ongoing Clinical Trials Overview | 135 | 1 |
| 5.79 Transbiomed, SL Company Overview | 136 | 1 |
| 5.79.1 Transbiomed, SL Pipeline Products &Ongoing Clinical Trials Overview | 136 | 1 |
| 5.80 Universite de Montreal Company Overview | 137 | 1 |
| 5.80.1 Universite de Montreal Pipeline Products &Ongoing Clinical Trials Overview | 137 | 1 |
| 5.81 University of South Florida Company Overview | 138 | 1 |
| 5.81.1 University of South Florida Pipeline Products &Ongoing Clinical Trials Overview | 138 | 2 |
| 5.82 US Biomarkers, Inc. Company Overview | 140 | 1 |
| 5.82.1 US Biomarkers, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 140 | 1 |
| 5.83 Vermillion, Inc. Company Overview | 141 | 1 |
| 5.83.1 Vermillion, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 141 | 2 |
| 5.84 Vitatex Inc. Company Overview | 143 | 1 |
| 5.84.1 Vitatex Inc. Pipeline Products &Ongoing Clinical Trials Overview | 143 | 2 |
| 5.85 Vitruvian Biomedical, Inc. Company Overview | 145 | 1 |
| 5.85.1 Vitruvian Biomedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 145 | 1 |
| 5.86 Yale University Company Overview | 146 | 1 |
| 5.86.1 Yale University Pipeline Products &Ongoing Clinical Trials Overview | 146 | 1 |
| 6 Ovarian Cancer Diagnostic Tests - Recent Developments | 147 | 87 |
| 6.1 Aug 18, 2016: MDxHealth Reports Second Quarter and First Half 2016 Results | 147 | 2 |
| 6.2 Aug 11, 2016: Metabolon Raises USD15 Million in Venture Financing | 149 | 1 |
| 6.3 Aug 11, 2016: GeneNews Announces Q2-2016 Financial Results | 149 | 1 |
| 6.4 Aug 10, 2016: Vermillion Reports Second Quarter 2016 Results | 149 | 1 |
| 6.5 Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results | 150 | 2 |
| 6.6 Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016 | 152 | 1 |
| 6.7 Aug 08, 2016: Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update | 153 | 2 |
| 6.8 Aug 04, 2016: Teva Reports Second Quarter 2016 Results | 155 | 4 |
| 6.9 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter | 159 | 2 |
| 6.10 Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results | 161 | 2 |
| 6.11 Aug 02, 2016: ASPiRA LABS Expands Coverage for OVA1 in California | 163 | 1 |
| 6.12 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results | 163 | 4 |
| 6.13 Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights | 167 | 2 |
| 6.14 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors | 169 | 1 |
| 6.15 Jul 27, 2016: Angle Announces Initiation Of 200 Patient United States Ovarian Cancer Study | 169 | 1 |
| 6.16 Jul 27, 2016: ASPiRA LABS Expands Coverage for OVA1 in Texas | 170 | 1 |
| 6.17 Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance | 171 | 2 |
| 6.18 Jul 21, 2016: Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 | 173 | 1 |
| 6.19 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 | 174 | 1 |
| 6.20 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 | 174 | 1 |
| 6.21 Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results | 175 | 2 |
| 6.22 Jul 20, 2016: Protagen Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member | 177 | 1 |
| 6.23 Jul 19, 2016: Angle Announces Initiation Of Two Hundred Patient European Ovarian Cancer Study | 178 | 1 |
| 6.24 Jul 19, 2016: ASPiRA LABS Announces Strategic Michigan Coverage for OVA1 | 179 | 1 |
| 6.25 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects | 179 | 6 |
| 6.26 Jul 18, 2016: Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 | 185 | 1 |
| 6.27 Jul 18, 2016: Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 | 186 | 1 |
| 6.28 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 | 186 | 1 |
| 6.29 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 | 187 | 1 |
| 6.30 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 | 187 | 1 |
| 6.31 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 | 188 | 1 |
| 6.32 Jul 15, 2016: PhRMA Welcomes Five New Member Companies | 188 | 1 |
| 6.33 Jul 13, 2016: Nasdaq Copenhagen accepts Exiqon request for delisting and cancellation from trading of the Exiqon shares | 189 | 1 |
| 6.34 Jul 13, 2016: Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives | 189 | 2 |
| 6.35 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia | 191 | 1 |
| 6.36 Jul 11, 2016: Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment | 192 | 1 |
| 6.37 Jul 04, 2016: Oncimmune Enters into Research Agreement with Egybiotech and Aarhus University Hospital | 192 | 1 |
| 6.38 Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board | 193 | 1 |
| 6.39 Jun 30, 2016: Tesaro Raises USD433.2 Million in Public Offering of Shares | 193 | 1 |
| 6.40 Jun 30, 2016: Tesaro to Raise up to USD55.8 Million in Public Offering of Shares | 193 | 1 |
| 6.41 Jun 29, 2016: Myriad's myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib | 193 | 1 |
| 6.42 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director | 194 | 1 |
| 6.43 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts | 195 | 1 |
| 6.44 Jun 15, 2016: GeneNews Announces Filing of Q1-2016 Financial Results | 195 | 1 |
| 6.45 Jun 10, 2016: Diadexus to File Chapter 7 | 196 | 1 |
| 6.46 Jun 04, 2016: T-Cell Receptor Sequencing Reveals Novel Biomarkers for Ovarian Cancer | 197 | 1 |
| 6.47 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 | 197 | 1 |
| 6.48 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 | 198 | 1 |
| 6.49 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 | 198 | 1 |
| 6.50 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 | 199 | 1 |
| 6.51 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 | 199 | 1 |
| 6.52 May 27, 2016: GeneNews Announces Full Year 2015 Financial Results | 200 | 1 |
| 6.53 May 25, 2016: Stage I Diagnostics Raises USD0.1 Million in Venture Financing | 201 | 1 |
| 6.54 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event | 201 | 2 |
| 6.55 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors | 203 | 1 |
| 6.56 May 19, 2016: GeneNews Announces a Further Extension of the TSX s Remedial Review Process | 203 | 1 |
| 6.57 May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis | 204 | 1 |
| 6.58 May 16, 2016: Vermillion to Showcase Comparison of Overa and ROMA Algorithms at ACOG 2016 Annual Meeting | 204 | 1 |
| 6.59 May 16, 2016: Nanosphere Announces First Quarter Results | 205 | 1 |
| 6.60 May 16, 2016: Vermillion Reports First Quarter 2016 Results | 206 | 1 |
| 6.61 May 16, 2016: Vermillion Reports Fourth Quarter and Full Year 2015 Results | 207 | 1 |
| 6.62 May 15, 2016: Luminex Acquires Nanosphere in Tender Offer | 208 | 1 |